top of page

Sepsis & Septic Shock

Publicยท397 members

https://www.nejm.org/doi/10.1056/NEJMoa2304748 In a trial, 661 patients with complicated UTI were randomized to receive cefepimeโ€“taniborbactam or meropenem. Of 436 in the microITT population, 70.6% on cefepimeโ€“taniborbactam vs. 58.0% on meropenem achieved composite success, showing superior efficacy (P=0.009). Safety profiles were similar.


Noor Shah
Hayat Sahlool

Effectiveness of Fludrocortisone Plus Hydrocortisone Versus Hydrocortisone Alone in Septic Shock: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials | American Journal of Respiratory and Critical Care Medicine | Articles in Press (atsjournals.org)

In a systematic review and Bayesian network meta-analysis of 17 trials (7,688 patients), fludrocortisone plus hydrocortisone showed a lower risk of all-cause mortality in adult septic shock compared to hydrocortisone alone and placebo/usual care. The combination treatment had a 0.85 relative risk of mortality (moderate-certainty evidence) and was 12% more effective than hydrocortisone alone (low-certainty evidence). The analysis relied mainly on indirect evidence due to limited direct comparisons.


Do you add fludrocortisone to your septic shock patients requiring hydrocortisone?

  • Yes

  • No


Ibrahim Ameen
Ibrahim Ameen
Souhila  Mansour
ูŠุงุณุฑ ุงู„ูˆุงู„ูŠ
Dr Mohammed Zakaria
Dr Mohammed Zakaria
12 fรฉvr.

Nowadays There is a very important role for midodrine and fludrocortizone in sepsis to maintain SBP specifically to reverse vasoplegia caused by sepsis

Sometimes we cannot wean pressors

Patients be in very low doses for long time and when pressors omitted blood pressure dropped again

These patient respond very well to midodrine and fludrocortisone

J'aime

Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial - The Lancet Respiratory Medicine


The PROPHY-VAP study, a multicenter, randomized trial in eight French hospitals, evaluated the efficacy of a single dose of ceftriaxone in preventing early ventilator-associated pneumonia (VAP) in 319 mechanically ventilated, comatose patients with acute brain injury. Patients were assigned to either ceftriaxone or placebo groups. The study found a significant reduction in early VAP incidence in the ceftriaxone group (14%) compared to the placebo group (32%), with no adverse effects. This led to the recommendation of including ceftriaxone in VAP prevention protocols for such patients.


Ibrahim Ameen
Dr.Mohammed ALnadabi
Fahd Yahya  Yahya
Ghali Alanazi

This used single ceftriaxone dose 2g within 12 hours of intubation. It targets eliminating colonisation in orotracheal tree to decrease VAP incidence in pt with high risk for aspiration(stroke, TBI, ICH, SAH)

. It shows less early VAP,less ventilated days, fewer ICU days, less abx usage, fewer Hopitalisation days, delayed VAP onset in ceftriaxone arm, and only two pt showed ESBL in rectal swab upon discharge in ceftriaxonearm.

The microbiological showed majority of polymicrobial yield

They included GCS 3 - 12 (majority were 4 - 8)


Thanks for sharing, Dr. Mazen


J'aime
bottom of page